HMCN1 variants aggravate epidermolysis bullosa simplex phenotype
Epidermolysis bullosa simplex (EBS) refers to a heterogeneous group of inherited skin disorders characterized by blister formation within the basal cell layer. The disease is characterized by marked variations in phenotype severity, suggesting co-inheritance of genetic modifiers. We identified three...
Saved in:
Published in | The Journal of experimental medicine Vol. 222; no. 5 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Rockefeller University Press
05.05.2025
|
Subjects | |
Online Access | Get full text |
ISSN | 0022-1007 1540-9538 1540-9538 |
DOI | 10.1084/jem.20240827 |
Cover
Summary: | Epidermolysis bullosa simplex (EBS) refers to a heterogeneous group of inherited skin disorders characterized by blister formation within the basal cell layer. The disease is characterized by marked variations in phenotype severity, suggesting co-inheritance of genetic modifiers. We identified three deleterious variants in HMCN1 that co-segregated with a more severe phenotype in a group of 20 individuals with EBS caused by mutations in KRT14, encoding keratin 14 (K14). HMCN1 codes for hemicentin-1. Protein modeling, molecular dynamics simulations, and functional experiments showed that all three HMCN1 variants disrupt protein stability. Hemicentin-1 was found to be expressed in human skin above the BMZ. Using yeast-2-hybrid, co-immunoprecipitation, and proximity ligation assays, we found that hemicentin-1 binds K14. Three-dimensional skin equivalents grown from hemicentin-1–deficient cells were found to spontaneously develop subepidermal blisters, and HMCN1 downregulation was found to reduce keratin intermediate filament formation. In conclusion, hemicentin-1 binds K14 and contributes to BMZ stability, which explains the fact that deleterious HMCN1 variants co-segregate with a more severe phenotype in KRT14-associated EBS. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 S. Bergson and O. Sarig contributed equally to this paper. Disclosures: V. Wally reported personal fees from Diaderm GmbH outside the submitted work; and holding shares of Diaderm GmbH, a company with an interest in drug development for EB. No other disclosures were reported. |
ISSN: | 0022-1007 1540-9538 1540-9538 |
DOI: | 10.1084/jem.20240827 |